# An Open-Label Treatment With Randomization Observation, Investigator-Initiated Study, on the Duration and Efficacy of Jornay PM (Methylphenidate Hydrochloride Extended-Release Capsules) on Adult ADHD Symptoms and Executive Function and Emotional Regulation Throughout the Day Into Early Evening

> **NCT06577779** · PHASE4 · RECRUITING · sponsor: **NYU Langone Health** · enrollment: 30 (estimated)

## Conditions studied

- Attention-deficit/Hyperactivity Disorder

## Interventions

- **DRUG:** Methylphenidate Hydrochloride Extended Release Capsule

## Key facts

- **NCT ID:** NCT06577779
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-29
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-10-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06577779

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06577779, "An Open-Label Treatment With Randomization Observation, Investigator-Initiated Study, on the Duration and Efficacy of Jornay PM (Methylphenidate Hydrochloride Extended-Release Capsules) on Adult ADHD Symptoms and Executive Function and Emotional Regulation Throughout the Day Into Early Evening". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06577779. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*